Citation: | LI Lin, WANG Xiaoming, MENG Shufang, CHEN Lin, WANG Haiyan, LIN Pengfei, CHEN Ling. Preparation process and structure confirmation of impurity C of rupatifen fumarate[J]. Journal of China Pharmaceutical University, 2020, 51(5): 530-537. DOI: 10.11665/j.issn.1000-5048.20200504 |
[1] |
.
|
[2] |
Fujian Mindong Rejuvenation Pharmaceutical Co.,Ltd.Rupatifen fumarate impurity C, preparation method and detection method thereof:CN,
201811043105.X[P]. |
[3] |
Wang C, Zhou MQ, Huang WC. Separation and structural confirmation of 5-methoxybenzo[d]oxazole-2(3H)-thione from key intermediate of omeprazole[J]. Chin J Synth Chem(合成化学), 2018, 26(4):284?287.
|
[4] |
CFDA.The technical guidelines for the preparation and structural confirmation of chemical drug apis[EB/OL].(
|
[5] |
ICH.Impurities in new drug substances(Q3A)[EB/OL].(
|
[6] |
Compania Uriach Y.Rupatadine salt as an antihistaminic agent:CN,
201180030958. X[P]. |
[7] |
Li LL.Study on the synthesis and impurity of rupatadine fumarate (富马酸卢帕他定的合成及杂质研究)[D].Hangzhou:Zhejiang University,2015.
|
[8] |
Zhao X.synthesis The,structure confirmation and qualitative analysis of rupatadine fumarate (富马酸卢帕他定的化学合成、结构确证和质量分析)[D].Jinan: Shandong University,2008.
|
[9] |
Hu CQ,Zhang X.Current situation and the trend in impurity profiling of chemical drugs[J].Acta Pharm Sin(药学学报),2019,54(12):2214?2231.
|